- Home
- XNCR vs OLMA Comparison
XNCR vs OLMA Comparison
Compare XNCR & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNCR | OLMA |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 937.1M | 863.0M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XNCR | OLMA |
|---|---|---|
| Price | $15.05 | $11.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $22.33 | ★ $44.89 |
| AVG Volume (30 Days) | 770.4K | ★ 1.7M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | 15.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,576,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 13.65 | N/A |
| 52 Week Low | $6.92 | $4.12 |
| 52 Week High | $18.69 | $36.26 |
Technical Indicators
Market Signals| Indicator | XNCR | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 73.30 | 49.34 |
| Support Level | $10.94 | $7.79 |
| Resistance Level | $15.59 | $11.54 |
| Average True Range (ATR) | 0.75 | 0.72 |
| MACD | 0.32 | 0.33 |
| Stochastic Oscillator | 80.78 | 79.93 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.